Multiple myeloma and malignant plasma cell neoplasms (C90) ICD-10-CM
The C90 code range covers multiple myeloma and malignant plasma cell neoplasms with 17 ICD-10-CM diagnosis codes. 12 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
- personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues Z85.79
Codes in the C90 Range 17 codes · 12 billable
- C90 Multiple myeloma and malignant plasma cell neoplasmsNon-billable
- C90.0 Multiple myelomaNon-billable
- C90.00 Multiple myeloma not having achieved remission
- C90.01 Multiple myeloma in remission
- C90.02 Multiple myeloma in relapse
- C90.1 Plasma cell leukemiaNon-billable
- C90.10 Plasma cell leukemia not having achieved remission
- C90.11 Plasma cell leukemia in remission
- C90.12 Plasma cell leukemia in relapse
- C90.2 Extramedullary plasmacytomaNon-billable
- C90.20 Extramedullary plasmacytoma not having achieved remission
- C90.21 Extramedullary plasmacytoma in remission
- C90.22 Extramedullary plasmacytoma in relapse
- C90.3 Solitary plasmacytomaNon-billable
- C90.30 Solitary plasmacytoma not having achieved remission
- C90.31 Solitary plasmacytoma in remission
- C90.32 Solitary plasmacytoma in relapse
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the C90 range.
Interleukin-6
A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
Smoldering Multiple Myeloma
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.
About the C90 Code Range
The ICD-10 codes in the C90 section classify various forms of multiple myeloma and related malignant plasma cell cancers. These codes help identify specific disease states including active disease, remission, and relapse.
This section covers multiple myeloma (C90.0) and its statuses such as not having achieved remission (C90.00), remission (C90.01), and relapse (C90.02). It also includes plasma cell leukemia (C90.1) with codes distinguishing remission and relapse phases. Additionally, the codes address extramedullary plasmacytoma (C90.2) and solitary plasmacytoma (C90.3), indicating whether these tumors are in remission, relapse, or active disease. The many listed synonyms for multiple myeloma, like light chain myeloma, IgG myeloma, myeloma kidney, and AL amyloidosis, clarify coding choices for complex presentations. These codes are essential for accurately documenting patients with plasma cell neoplasms, facilitating precise communication and treatment planning. Searching for "ICD-10 code for multiple myeloma" will lead to these detailed options tailored to the patient’s current disease status.
Questions About This Page
How many billable codes are in the C90 range?
Of the 17 codes in this range, 12 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the C90 range classify?
The range classifies multiple myeloma and malignant plasma cell neoplasms. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
